Skip to main content
SpringerLink
Log in

Monitoring Coagulation Proteins During Progression of Liver Disease

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

This work was designated to monitor the coagulation abnormalities associated with the gradual progression of liver diseases. The study included fifty patients; forty were diagnosed with liver cirrhosis with different stages categorized according to the Childs-Pugh classification and another ten patients were diagnosed with hepatocellular carcinoma (HCC). Haemostatic variables including fibrinogen (FI), calcium (FIV), transglutaminase (FXIII), prothrombin time (PT) and platelet count were estimated in patients and compared with the baseline levels of healthy subjects (n = 10). The results demonstrated that the fibrinogen level was progressively decreased, whereas PT was progressively prolonged in Child A, Child B and Child C groups. The maximum deterioration was observed in HCC patients. Calcium significantly increased in mild (Child A) and moderate (Child B) but not in Child C cirrhosis and HCC patients. FXIII level did not show any significant changes in cirrhotic patients compared to healthy group. Some of the haemostatic variables we investigated were correlated with serum albumin and bilirubin but not with aminotransferases (ALT and AST). The results indicated that the haemostatic abnormalities in fibrinogen, calcium and PT (but not FXIII) were deteriorated in parallel with the gradual regression of the constitutional function of liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Muciño-Bermejo J, Carrillo-Esper R, Uribe M, Méndez-Sánchez N. Coagulation abnormalities in the cirrhotic patient. Ann Hepatol. 2013;12(5):713–24.

    PubMed  Google Scholar 

  2. Páramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost. 1993;19(3):184–90.

    Google Scholar 

  3. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding esophageal varices. Br J Surg. 1973;60:646–9.

    Article  CAS  PubMed  Google Scholar 

  4. Solomon L. Hematologic complications of liver disease and alcoholism. In: Hoffman R, Benz E, editors. Basic principles and practice of hematology. New York: Churchill Livingstone; 1994.

    Google Scholar 

  5. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22(1):83–96.

    Article  CAS  PubMed  Google Scholar 

  6. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am. 1992;6(6):1247–57.

    CAS  PubMed  Google Scholar 

  7. Tripodi A. Hemostasis in chronic liver disease. Thromb Haemost J. 2006;4(9):2064–5.

    Article  CAS  Google Scholar 

  8. Wang FJ, Cao J, Ma LP, Jin ZX. Study on cellular and serum concentration of calcium and magnesium in peripheral blood cells of cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2004;12(3):144–7.

    CAS  PubMed  Google Scholar 

  9. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131–9.

    Article  CAS  PubMed  Google Scholar 

  10. Tacke F, Fiedler K, Von Depka M, Luedde T, Hecker H, Manns MP, et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int. 2006;26(2):173–81.

    Article  CAS  PubMed  Google Scholar 

  11. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat. 1957;17:237–46.

    Article  CAS  PubMed  Google Scholar 

  12. Flckensher K, Aab A, Stüber W. A photometric assay for blood coagulation factor XIII Thromb. Haemostasis. 1991;65:353–540.

    Google Scholar 

  13. Faulkner WR, Meites S. Selected methods of clinical chemistry, vol. 9. Washington DC: American Association for Clinical Chemistry; 1982.

    Google Scholar 

  14. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis. 2007;27(4):413–26.

    Article  CAS  PubMed  Google Scholar 

  15. Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Bailliere’s Best Pract Res Clin Gastroenterol. 2000;14(2):211–28.

    Article  CAS  Google Scholar 

  16. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factor of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–9.

    Article  CAS  PubMed  Google Scholar 

  17. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA. 2010;107:14757–62.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Shi L, Zhhang SL, Li K, Hong Y, Wang Q, Li Y, et al. NS5ATP9, a gene up regulated by HCV NS5A protein. Cancer Lett. 2008;259(2):192–7.

    Article  CAS  PubMed  Google Scholar 

  19. Turcotte J, Child C. The liver and portal hypertension. In: Child CI, editor. Surgery and portal hypertension. Philadelphia: WB Saunders; 1964. p. 50–8.

    Google Scholar 

  20. Ordinas A, Escolar G, Cirera I, Viñas M, Cobo F, Bosch J, et al. Existence of a platelet–adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology. 1996;24(5):1137–42.

    Article  CAS  PubMed  Google Scholar 

  21. Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJJ, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA. 1990;87:7623–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Blombäck B, Blombäck M. The molecular structure of fibrinogen. Ann NY Acad Sci. 1972;202:77–97.

    Article  PubMed  Google Scholar 

  23. Arif S, Khan AS, Khan AR. Changes in fibrinogen level in liver cirrhosis. J Ayub Med Coll Abbottabad. 2002;14(2):19–21.

    PubMed  Google Scholar 

  24. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992;15(4):672–6.

    Article  CAS  PubMed  Google Scholar 

  25. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol. 2001;96(5):1581–6.

    Article  CAS  PubMed  Google Scholar 

  26. Miatto O, Casaril M, Gabrielli GB, Nicoli N, Bellisola G, Corrocher R. Diagnostic and prognostic value of serum copper and plasma fibrinogen in hepatic carcinoma. Cancer. 1985;55(4):774–8.

    Article  CAS  PubMed  Google Scholar 

  27. Martinz J, Palascak J, Kawasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest. 1978;61(2):535–8.

    Article  Google Scholar 

  28. Ratnoff OD, Forman WB. Criteria for the differentiation of dysfibrinogenemia states. Semin Hematol. 1976;13:141–57.

    CAS  PubMed  Google Scholar 

  29. Davi EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 1991;30(43):10363–70.

    Article  Google Scholar 

  30. Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparison of child and acute physiology, age and chronic health evaluation (APACHE 111) scoring systems. Am J Gastroenterol. 1998;93:2469–75.

    Article  CAS  PubMed  Google Scholar 

  31. Grimaudo S, Craxi A, Gentile S, Di Paolantonio T, Vaccaro A, Venezia G, et al. Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. Dig Liver Dis. 2005;37:446–50.

    Article  CAS  PubMed  Google Scholar 

  32. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247–99.

    Article  CAS  PubMed  Google Scholar 

  33. El Borai MS, Ibrahim WM, Hessien M, El-keey M. Effect of alpha-tocopherol on tissue transglutaminase and reversibility of thioacetamide-induced liver fibrosis in rats. Turkish J of Biochem. 2005;31(1):13–20.

    Google Scholar 

  34. Klingemann HG, Brunswig D, Liehr H. Fibrinogen and fibrin structure in patients with cirrhosis of the liver. Z Gastroenterol. 1978;16(9):564–73.

    CAS  PubMed  Google Scholar 

  35. Knittel T, Fellmer P, Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology. 1996;111:745–54.

    Article  CAS  PubMed  Google Scholar 

  36. Abdel-Aziz G, Lebeau G, Rescan PY. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. Am J Pathol. 1990;137:1333–42.

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J, Schwarting R, Norton P, Zern MA, et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol. 1997;272(2):281–8.

    Google Scholar 

  38. Ikura Y, Ohsawa M, Okada M, Iwai Y, Wakasa K. The significance of platelet consumption in the development of thrombocytopenia in patients with cirrhosis. Am J Med Sci. 2013;346(3):199–203.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Mohamed Hessien

    Present address: Department of Clinical Biochemistry, College of Medicine, KKU, Abha, Kingdom of Saudi Arabia

Authors and Affiliations

  1. Department of Chemistry, Division of Biochemistry, Faculty of Science, Tanta University, Tanta, Egypt

    Mohamed Hessien, Mohamed Ayad & Batoul Izz ulArab

  2. Department of Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt

    Wafaa M. Ibrahim

Authors
  1. Mohamed Hessien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Ayad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wafaa M. Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Batoul Izz ulArab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Hessien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hessien, M., Ayad, M., Ibrahim, W.M. et al. Monitoring Coagulation Proteins During Progression of Liver Disease. Ind J Clin Biochem 30, 210–216 (2015). https://doi.org/10.1007/s12291-014-0429-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-014-0429-1

Keywords

Search

Navigation